LifeVantage Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2017. Although the request references “2016 Q4,” this filing is the FY2017 annual report; fourth-quarter results are noted separately below. Financial statements are audited, and comparative FY2016 and FY2015 figures were revised for immaterial income-tax errors.
Business context
LifeVantage sells nutraceutical supplements and skin-care products through an international direct-selling network. Its principal product lines are Protandim and TrueScience. The United States and Japan generated approximately 73% and 20% of FY2017 revenue, respectively. The company reported approximately 64,000 active distributors and 112,000 active preferred customers at year-end.
Key financial results
| Metric | FY2017 | FY2016, revised | Change |
|---|---|---|---|
| Net revenue | $199.5 million | $206.5 million | Down 3.4% |
| Gross profit / margin | $166.0 million / 83.2% | $172.6 million / 83.6% | Margin down 0.4 percentage points |
| Operating income / margin | $4.4 million / 2.2% | $13.4 million / 6.6% | Down $9.0 million |
| Net income | $1.6 million | $6.1 million | Down 73.7% |
| Diluted EPS | $0.11 | $0.42 | Down $0.31 |
| Cash from operations | $6.6 million | $6.0 million | Up $0.6 million |
FY2017 revenue by major product line: Protandim $130.9 million (65.6% of revenue), TrueScience $24.4 million (12.3%), and other products $44.2 million (22.1%).
Fourth-quarter FY2017 revenue was $50.6 million and net income was $0.08 million; diluted EPS was $0.01. The filing does not provide a clear standalone fourth-quarter cash-flow value.
Liquidity, debt and cash flow
- Cash and cash equivalents were $11.5 million at June 30, 2017, up from $7.9 million a year earlier; working capital was $12.2 million, versus $12.5 million.
- Operating cash flow was $6.6 million; investing cash use was $1.1 million, primarily capital expenditures; financing cash use was $2.0 million, primarily term-loan principal payments.
- Term-loan principal outstanding was $7.5 million, including $2.0 million current and $5.5 million long-term. The term loan bears fixed interest of 4.93%, matures in March 2019, and is secured by substantially all company assets. A revolving facility of up to $2.0 million is also available.
- The company reported compliance with financial covenants at year-end and said cash plus expected operating cash flow should meet requirements for at least the next 12 months. The credit agreement restricts additional borrowing, certain transactions and dividends.
Changes and management outlook
- Revenue fell mainly because of lower U.S. and Hong Kong sales. Americas revenue declined 4.7%; Asia/Pacific & Europe revenue increased 0.8%, including Japan growth partly due to favorable currency translation.
- Active distributors declined 7.2% year over year and active preferred customers declined 4.3%. The company attributed some sales declines to tighter international controls following its audit committee review.
- Revenue from sales that may have been carried or shipped into countries with registration or direct-selling restrictions was estimated at $3.0 million in FY2017, down from $17.3 million in FY2016.
- Gross margin was pressured by inventory obsolescence, storage, handling and shipping costs. Management expected gross margin to remain in the 83%–85% range for the foreseeable future.
- SG&A increased $8.8 million to $64.9 million, primarily due to legal and accounting costs related to the independent review, higher event spending, and employee and executive-transition costs. Inventory-obsolescence expense rose to $1.3 million from $0.3 million.
- Management cited distributor tools, training, technology, product development and international expansion as growth initiatives. It expected moderate growth in Asia/Pacific & Europe and anticipated a China e-commerce launch in the near term; no numerical revenue or earnings guidance was provided.
Material matters, risks and contingencies
- Prior-period revisions: Immaterial income-tax errors were corrected in historical statements. Management treated the corrections as a GAAP restatement; it said the cumulative effect of applying them only in FY2017 would have been material. FY2016 net income was revised upward by $87,000 and FY2015 by $138,000.
- Controls: The audit committee’s 2016 review identified sales into restricted or unregistered markets and a material weakness in international-business controls. Management said remediation was complete and controls were effective at June 30, 2017; the auditor issued unqualified opinions on the financial statements and internal controls.
- Regulatory: The company received an FDA warning letter in April 2017 alleging impermissible drug claims on its website concerning Protandim Nrf2 Synergizer. It disputed factual assertions, responded, and reported no further FDA correspondence as of the filing.
- Litigation: A securities class action and several derivative actions alleged misleading statements and control failures relating to FY2016 reporting. The class-action complaint was dismissed without prejudice; plaintiffs later sought leave to amend. The company recorded no loss accrual, stating a loss was not probable or estimable, but warned an adverse outcome could materially affect the business.
- Concentration and operating risks: Protandim and TrueScience generated 77.9% of revenue combined. Other significant risks include distributor retention, direct-selling and product-claim regulation, dependence on third-party manufacturers and suppliers, product liability and recall exposure, inventory management, foreign exchange (especially the yen), and debt covenants.
- Management reported no probable loss contingencies requiring accrual or disclosure in the financial statements. The company does not maintain product-recall insurance.
Most important facts for investors to verify
- Whether distributor and customer counts stabilize and revenue recovers, particularly in the U.S. and Japan, after the policy changes.
- Progress and costs in maintaining the remediated international controls, and any further regulatory or legal developments related to the 2016 review and FDA warning letter.
- Whether the class and derivative actions advance, and whether any resulting exposure becomes estimable or requires an accrual.
- Inventory levels, obsolescence charges and the sustainability of management’s 83%–85% gross-margin expectation.
- Cash generation, debt repayment, covenant compliance and liquidity under weaker revenue or adverse currency movements.
- Evidence that newer products and planned digital or international initiatives can offset dependence on Protandim and TrueScience.